Immunosuppressive Treatment in Glomerular Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 184
Special Issue Editors
Interests: intrinsic kidney pathology
Special Issue Information
Dear Colleagues,
Immunosuppressive treatment has remained the cornerstone option in managing glomerular diseases. There are various classes of immunosuppressive therapies, such as alkylating agents, antimetabolites, calcineurin inhibitors, anti-CD20 therapy, complement inhibitors, corticosteroids, and intravenous immunoglobulin, which all have their respective advantages and disadvantages as a treatment option in this setting. Whilst the basic mechanisms for most of these medications are relatively well understood, ongoing research to determine the pharmacodynamics, pharmacokinetics, optimal monitoring, and adverse profiles of these drugs continues to excite the field. The key to managing glomerular diseases with immunosuppression is to maintain an ideal balance between disease mitigation and minimizing adverse treatment effects. In an age of personalized medicine and goal-directed care, finding the right strategies for induction and maintenance regimens and altering immunosuppression prescriptions depending on disease progression and response to treatment are imperative in achieving optimal clinical outcomes, including patient-reported outcomes. Consideration for special situations such as pregnancy, old age and frailty, and concurrent kidney replacement therapy also needs to be given during immunosuppressive treatment prescriptions for glomerular disease.
We present a Special Issue which aims to address these various facets of immunosuppression treatment in glomerular disease, and we welcome submissions across basic, translational, and clinical research which discuss this important topical area.
Dr. Henry H.L. Wu
Dr. Rajkumar Chinnadurai
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunosuppressive treatment
- glomerular diseases
- nephrology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
